HypocalcemiaPhase 4DexaNCT04412694
The Effect of Preoperative Oral Dexamethasone Supplementation on the Outcome of Thyroidectomised Patients.
A Phase 4 study testing Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland)., Preoparative blood laboratory tests and Postoperative laboratory blood tests at 6 hour in people with Hypocalcemia and Vitamin D Deficiency, run by Medical University of Lodz at 1 site in Poland.
Trial summary
Glucocorticoids are well known for their analgesic, anti-inflammatory, immunomodulatory and anti-emetic effects. Recovery time after thyroid surgery may depend on several factors, such as postoperative pain, nausea and vomiting, postoperative sore throat, voice disorders and symptomatic hypocalcaemia (low serum… Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Hypocalcemia, Vitamin D Deficiency, Postoperative Complications
- What is being tested?
- Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland)., Preoparative blood laboratory tests and Postoperative laboratory blood tests at 6 hour
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 sitePoland
- Study dates
- 1 Jul 2020to Dec 2022
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- patient's consent
- adult patients
- preoperative diagnosis of nontoxic multinodular goiter
- total thyroidectomy
Who cannot join
- lack of patient's consent
- hyperthyroidism currently or in the past
- retrosternal goiter
- thyroid malignanacy or suspected malignant thyroid tumor
- parathyroids disease
- malingant tumor in any location currently or in the past
Show all 39Show fewer
- state after neck surgery
- state after radiotherapy
- bone diseases, osteoporosis
- sarcoidosis
- liver failure, hepatitis
- kidney stones, kidney failure (eGFR<60ml/min/1.73m2)
- taking nonsteroidal anti-inflammatory drugs
- steroid treatment
- stomach and duodenal ulcer disease currently or in the past
- active infection at the time of the study
- history of tuberculosis
- a period of 8 weeks before and 2 weeks after administration of the live vaccine
- unregulated hypertension
- diabetes
- psychiatric disorders
- glaucoma
- corneal ulcers or corneal injuries
- severe heart failure
- pheochromocytoma
- myasthenia gravis
- epilepsy
- head injury
- ulcerative colitis
- diverticulitis
- pregnancy
- breast-feeding
- hypokalaemia
- galactose intolerance
- lactase deficiency
- dexamethasone allergy, allergic to lactose, allergic to gelatinized starch, allergic to corn starch, allergic to colloidal anhydrous silica, allergic to magnesium stearate
- allergic reaction to substances contained in the sweetener: sodium cyclamate, sodium saccharin, sodium bicarbonate, sodium citrate.
- taking medications that affect calcium metabolism: anti-resorptive drugs, anabolic drugs, bisphosphonates, systemic glucocorticosteroids, thiazide diuretics, furosemide, proton pump inhibitors, antacids containing magnesium or aluminum salts, cholestyramine, colestipol, paraffin oil, salicylates, estrogen-containing oral contraceptives (hormonal contraceptives) , preparations containing calcium salts (regular intake), preparations of vitamin D or its analogues (regular intake)
- taking medications that increase the side effect of dexamethasone or enter into drug interactions with dexamethasone: acetazolamide, loop diuretics, thiazide diuretics, diuretics, amphotericin B, glucocorticosteroids, mineralocorticosteroids, tetracosactide and laxatives, carbenoxolone, chlorokine, hydroxychlorokine and meflocin, angiotensin converting enzyme inhibitors, thalidomide, cholinesterase inhibitors in patients with myasthenia gravis, fluorochonolones, ephedrine, barbiturates, rifabutin, rifampicin, phenytoin and carbamazepine, aminoglutethimide, bile acid binding resins, such as cholestyramine, antacids,activated carbon, antifungal azoles, ketoconazole, HIV protease inhibitors, macrolide antibiotics, estrogens, anti-tuberculosis drugs (isoniazid), cyclosporin, praziquantel, oral anticoagulants (coumarin), atropine and other anticholinergic drugs, somatotropin, protirel.
Trial locations and contacts
1 site in 1 country.
Poland1 site, 1 recruiting
- Recruiting
Department of General and Oncological Surgery, Medical University of Lodz
Lodz, Łódź Voivodeship, 92-213
Anna Grzegory, MD, 695720008, an.grzegory@gmail.com
About this study
Official title: The Impact of Preoperative Oral Dexamethasone Supplementation on the Biochemical Parameters and Results of Surgical Treatment in Patients With Nontoxic Multinodular Goiter Undergoing Total Thyroidectomy.
Glucocorticoids are well known for their analgesic, anti-inflammatory, immunomodulatory and anti-emetic effects. Recovery time after thyroid surgery may depend on several factors, such as postoperative pain, nausea and vomiting, postoperative sore throat, voice disorders and symptomatic hypocalcaemia (low serum calcium level). However, there is little information in the literature about the preventive use of glucocorticosteroids in patients undergoing thyroid surgery. The aim of the study is to evaluate the clinical impact of preoperative oral dexamethasone supplementation on the surgical outcome in patients with multinodular goiter undergoing total thyroidectomy. Patients will be assigned to the supplementation group and the placebo group. In the supplementation group 8mg of dexamethasone will be administered orally one hour before surgery. In the postoperative period, the frequency and intensity of pain, nausea, vomiting, sore throat and hoarseness will be assessed. The incidence of symptoms of hypocalcaemia will also be evaluted. Preoperative and postoperative levels of vitamin D, cytokines, acute phase proteins and substances related to calcium metabolism will be measured in the blood. Cytokines levels in drainage fluid will also be assessed. The main hypothesis of the study is that in patients with supplementation postoperative discomfort and decrease in serum calcium and parathormone level and hypocalcemic symptoms will be less severe and the levels of proinflammatory substances will be decreased.
Read the detailed description
Recovery time after thyroid surgery may depend on several factors, such as postoperative pain, nausea and vomiting, postoperative sore throat, phonation disorders associated with recurrent laryngeal nerve palsy, and symptomatic postoperative hypocalcaemia associated with postoperative hypoparathyroidism.
Glucocorticoids are well known for their analgesic, anti-inflammatory, immunomodulatory and anti-emetic effects. However, there is little information in the literature on the prophylactic use of glucocorticosteroids in patients undergoing thyroid surgery. In some previous studies, preoperative intravenous dexamethasone supplementation was associated with a reduced incidence of postoperative laryngeal nerve palsy, postoperative hypoparathyroidism, and with less severe postoperative pain, postoperative sore throat, nausea and vomiting. Patients receiving supplementation also had decreased levels of inflammatory biochemical parameters and proinflammatory cytokines.
Vitamin D deficiency is widespread in Poland. Vitamin D status has an impact on the postoperative complications in surgical patients. In previous study serum 25-hydroxyvitamin D is also suggested as a negative acute phase reactant, which has implications for acute and chronic inflammatory diseases. According to the authors, serum 25-hydroxyvitamin D level is an unreliable biomarker of vitamin D status after acute inflammatory insult.
In the early stages of inflammation, phagocytic cells and endothelium secrete proinflammatory cytokines, which include: interleukins: IL-1 α / β, IL-6, IL-8, TNF. The antagonistic group is anti-inflammatory cytokines, which include interleukins: IL-4, -5, -10, -13, produced by Th2 lymphocytes. These cytokines reduce the amount of interleukins secreted by Th1 lymphocytes.
Changes in the levels of proinflammatory and anti-inflammatory cytokines in the postoperative period were found in studies related to the assessment of surgical trauma. Pro-inflammatory interleukin 1 and interleukin 6 play an important role in many biological processes such as inflammation, sepsis and wound healing. Interleukin 6 expression is proportional to the extent of the surgical trauma. In turn, interleukin 10 is known as a cytokine that inhibits cytokine synthesis. Is one of the strongest immunosuppressive agents.
The aim of my study is to evaluate the impact of preoperative oral dexamethasone supplementation on the biochemical parameters and results of surgical treatment in patients with nontoxic multinodular goiter undergoing total thyroidectomy.
Patients admitted to the Department of General and Oncological Surgery, Medical University of Lodz with preoperative diagnosis of nontoxic multinodular goitre undergoing total thyroidectomy will be inculded to the study.
After obtaining written informed consent from all participants during a preoperative visit, they will be randomized to the supplementation group and the placebo group. The study will be a prospective, placebo-controlled and double-blind (for patient and surgeon) research.
Intervention: In the supplementation group a single dose of 8mg of dexamethasone will be given orally one hour before surgery (Dexamethasone Krka tablets (8mg), Warsaw, Poland). In the placebo group patients will receive a single tablet of sweetener one hour before operation (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria).
Preoperatively in the group of all enrolled patients (in the supplementation group and in the placebo group) following tests will be measured in serum: blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10, thyroid stimulating hormone, free thyroxine, free triiodothyronine.
Total thyroidectomies with routine identification of the recurrent laryngeal nerves and parathyroid glands via a transverse cervicotomy under general anaesthesia will be performed by 3 experienced surgeons.
During the total thyroidectomy the number of parathyroid glands found intraoperatively will be registered.
At 6 hour after surgery in the group of all enrolled patients following tests will be measured in serum: blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium. In addiction, at 6 hour after surgery the incidence and intensity of symptomatic hypocalcaemia, postoperative pain (according to VAS scale), postoperative nausea and vomiting, postoperative sore throat and hoarseness will be evaluated.
At 24 hour after surgery in the group of all enrolled patients following tests will be measured in serum: blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10. Additionally, the level of interleukin 1β, interleukin 6 and interleukin 10 will be evaluated in drainage fluid. In addiction, at 24 hour after surgery the incidence and intensity of symptomatic hypocalcaemia, postoperative pain (according to Visual Analogue Scale - VAS scale), postoperative nausea and vomiting, postoperative sore throat and hoarseness will be evaluated.
The laboratory parameters will be determined by electrochemiluminescence on the Cobas E411 analyzer and spectrophotometric method on the AU680, Beckman Coulter analyzer. 25-hydroxyvitamin D levels will be measured using the chemiluminescent microparticle immunoassay (CMIA) (Architect 25-OHD). Interleukins levels will be determined by enzyme immunoassay method (EIA) (DGR Medtek) on ElizaMat 2 X analyzer.
Hypocalcemic symptoms will be categorized as mild (a tingling sensation and numbness of the hands or feet and perioral numbness) or severe (a positive Chvostek sign, Trousseau sign, tetany, and carpopedal spasms).
Postoperative hypocalcaemia will be defined as corrected calcium levels <2.0 mmol/l, even if recorded in one measurement only.
In both groups participants who will develop postoperative hypoparathyroidism (parathormone level <1.6 pmol/l at 6 or 24 hour after surgery) or symptomatic hypocalcaemia during hospitalisation will be treated with oral calcium (3 g/d - taken 1 g every 8 hours) and vitamin D derivatives (1 ug/d alfacalcidol taken once).
Intravenous calcium gluconate will be administered if symptoms persist despite oral supplementation.
Patients with symptomatic hypocalcaemia will receive supplementation until the symptoms subside. The treatment will be extended to 6 weeks in patients with hypoparathyroidism on the day of discharge.
The data will be statistically analysed. The main hypothesis of the study is that in patients with supplementation postoperative discomfort and decrease in serum calcium and parathormone level and hypocalcemic symptoms will be less severe and the levels of proinflammatory substances will be decreased. Vitamin D deficiency is probably common in operated patients and postoperative 25-hydroxyvitamin D levels are lower than those measured preoperatively.
The use of oral dexamethasone might be an effective strategy of prevention of complications after total thyroidectomy.
To the best of our knowledge, this is a pioneering study assessing the usefulness of preventive oral dexamethasone supplementation before total thyroidectomy in homogeneous group of patients with nontoxic multinodular goiter undergoing total thyroidectomy.
- Conditions
- Hypocalcemia, Vitamin D Deficiency, Postoperative Complications, Postoperative Nausea, Postoperative Pain, Voice Hoarseness
- Being tested
- Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland)., Placebo oral sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria)., Preoparative blood laboratory tests, Postoperative laboratory blood tests at 6 hour, Postoperative laboratory blood tests at 24 hour
- Keywords
- dexamethasone, hypocalcaemia, hypocalcemic symptoms, postoperative complications, vitamin D deficiency, cytokines, postoperative pain, postoperative nausea, postoperative vomiting, hoarseness, acute phase proteins, hypoparathyroidism
- Medical subject headings
- Hypocalcemia, Vitamin D Deficiency, Postoperative Complications, Postoperative Nausea and Vomiting, Pain, Postoperative, Hoarseness, Hypoparathyroidism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland).Drug
Also called Supplementation
Preoperative oral dexamathasone supplementation in a single dose of 8mg.
Placebo oral sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria).Drug
Also called Placebo
Preoperative oral supplementation of sweetener in a single dose.
Preoparative blood laboratory testsDiagnostic test
Also called preoperative blood test
Preoperative parameters such as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10, thyroid stimulating hormone, free thyroxine, free triiodothyronin will be measured in serum.
Postoperative laboratory blood tests at 6 hourDiagnostic test
Also called blood tests 6 hour
At 6 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium will be measured in serum.
Postoperative laboratory blood tests at 24 hourDiagnostic test
Also called blood tests 24 hour
At 24 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10 will be measured in serum.
Postoperative laboratory drainage fluid tests at 24 hourDiagnostic test
Also called drainage fluid tests 24 hour
At 24 hour after surgery such parameters as interleukin 1β, interleukin 6, interleukin 10 will be measured in drainage fluid.
Total thyroidectomyProcedure or surgery
Also called thyroidectomy
Patients will undergo total thyroidectomy under general anesthesia.
Symptomatic hypocalcaemia at 6 hourOther
Also called symptoms 6 hour
At 6 hour after surgery patients will be assessed for signs of hypocalcaemia.
Symptomatic hypocalcaemia at 24 hourOther
Also called symptoms 24 hour
At 24 hour after surgery patients will be assessed for signs of hypocalcaemia.
Postoperative pain at 6 hourOther
Also called pain 6 hour
At 6 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
Postoperative pain at 24 hourOther
Also called pain 24 hour
At 24 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS).
Postoperative nausea and vomiting at 6 hourOther
Also called nausea 6 hour
At 6 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
Postoperative nausea and vomiting at 24 hourOther
Also called nausea 24 hour
At 24 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated.
Postoperative sore throat and hoarseness at 6 hourOther
Also called hoarseness 6 hour
At 6 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated.
Postoperative sore throat and hoarseness at 24 hourOther
Also called hoarseness 24 hour
At 24 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated.
| Study group | Role | What they receive |
|---|---|---|
| supplementation group | Experimental | Patients will receive preoperative oral supplementation of 8mg of dexamethasone (Dexamethasone Krka tablets (8mg), Warsaw, Poland) in a single dose taken once one hour before surgery. At 6 and 24 hour after surgery, clinical and laboratory parameters will be measured and evaluated. Receives: Drug: Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland).; Diagnostic Test: Preoparative blood laboratory tests; Diagnostic Test: Postoperative laboratory blood tests at 6 hour; Diagnostic Test: Postoperative laboratory blood tests at 24 hour; Diagnostic Test: Postoperative laboratory drainage fluid tests at 24 hour; Procedure: Total thyroidectomy; Other: Symptomatic hypocalcaemia at 6 hour; Other: Symptomatic hypocalcaemia at 24 hour; Other: Postoperative pain at 6 hour; Other: Postoperative pain at 24 hour; Other: Postoperative nausea and vomiting at 6 hour; Other: Postoperative nausea and vomiting at 24 hour; Other: Postoperative sore throat and hoarseness at 6 hour |
| placebo group | Placebo comparator | Patients will receive preoperative oral supplementation of sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria) taken once in a single dose one hour before surgery. At 6 and 24 hour after surgery, clinical and laboratory parameters will be measured and evaluated. Receives: Drug: Placebo oral sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria).; Diagnostic Test: Preoparative blood laboratory tests; Diagnostic Test: Postoperative laboratory blood tests at 6 hour; Diagnostic Test: Postoperative laboratory blood tests at 24 hour; Diagnostic Test: Postoperative laboratory drainage fluid tests at 24 hour; Procedure: Total thyroidectomy; Other: Symptomatic hypocalcaemia at 6 hour; Other: Symptomatic hypocalcaemia at 24 hour; Other: Postoperative pain at 6 hour; Other: Postoperative pain at 24 hour; Other: Postoperative nausea and vomiting at 6 hour; Other: Postoperative nausea and vomiting at 24 hour; Other: Postoperative sore throat and hoarseness at 6 hour; Other: Postoperative sore throat and hoarseness at 24 hour |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative hypocalcaemia
To evaluate the incidence of laboratory hypocalcaemia (corrected calcium serum level <2.0 mmol/l), the change in calcium levels and symptomatic hypocalcaemia in the postoperative period in the supplementation group and in the placebo group.
Measured: preoperatively and at 6 and 24 hour after surgery
Postoperative hypoparathyroidism
To evaluate the incidence of hypoparathyroidism (parathormone serum level <1.6 pmol/l) and the change in parathormone levels in the postoperative period in the supplementation group and in the placebo group.
Measured: preoperatively and at 6 and 24 hour after surgery
Secondary outcomes (5)
Postoperative pain
To evaluate the intensity of postoperative pain according to Visual Analogue Scale (VAS scale) in the postoperative period in the supplementation group and in the placebo group. Minimum value is 0 (no pain) and maximum value is 10 (the worst possible pain). Higher scores mean a worse outcome.
Measured: at 6 and 24 hour after surgery
Postoperative nausea on a verbal rating scale
To evaluate the incidence and the intensity of postoperative nausea in the postoperative period in the supplementation group and in the placebo group. The intensity of nausea will be rated on a verbal rating scale based on verbal responses of the patient to questions: 0 - no nausea; 1 - mild nausea (1 episode of nausea); 2 - moderate nausea (2 or 3 episodes of nausea ); and 3 - severe nausea (>3 episodes of nausea ). Higher scores mean a worse outcome.
Measured: at 6 and 24 hour after surgery
Postoperative vomiting on a verbal rating scale
To evaluate the incidence and the intensity of postoperative vomiting in the postoperative period in the supplementation group and in the placebo group.The intensity of vomiting will be rated on a verbal rating scale based on verbal responses of the patient to questions: 0 - no episodes of vomiting; 1 - mild vomiting (1 episode of vomiting); 2 - moderate vomiting (2 or 3 episodes of vomiting); and 3 - severe vomiting (>3 episodes of vomiting).Higher scores mean a worse outcome.
Measured: at 6 and 24 hour after surgery
Postoperative sore throat on a verbal rating scale
To evaluate the incidence and the intensity of postoperative sore throat in the postoperative period in the supplementation group and in the placebo group. Postoperative sore throat will be defined as discomfort at larynx or pharynx at rest and during swallowing after surgery. The intensity of sore throat will be rated on a verbal rating scale based on verbal responses of the patient to questions: 0 - none; 1 - mild sore throat (less severe than with a cold); 2 - moderate sore throat (similar with a cold); and 3 - severe sore throat (more severe than with a cold). Higher scores mean a worse outcome.
Measured: at 6 and 24 hour after surgery
Postoperative hoarseness on a verbal rating scale
To evaluate the incidence and the intensity of postoperative hoarseness in the postoperative period in the supplementation group and in the placebo group. The intensity of hoarseness will be rated on a verbal rating scale based on verbal responses of the patient to questions: 0 - none; 1 - mild hoarseness (noticed by the patient only); 2 - severe hoarseness (obvious to observer); 3 - aphonia (silence of voice). Higher scores mean a worse outcome.
Measured: at 6 and 24 hour after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jun 2020
- Study start1 Jul 2020
- Primary completionSep 2022 (estimated)
- Study completionDec 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (11)Papers the sponsor has linked to this study.
- Other trials for HypocalcemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Patients will be randomly assigned (coin toss) to the supplementation group (preoperative oral supplementation of dexamethasone (8mg in one dose) taken one hour before surgery) and to the placebo group (preoperative oral supplementation of sweetener taken one hour before surgery).
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medical University of Lodz
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Anna Grzegory, Medical University of Lodz
- Investigators
- Anna Grzegory, MD, Principal investigator, Medical University of Lodz, Poland
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04412694
- Sponsor's protocol ID
- MULODZ nr RNN/133/20/KE
- Acronym
- Dexa
- Status last verified
- Feb 2022
- First submitted
- 23 May 2020
- Last updated
- 8 Feb 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All IPD will be included in planned publication.
Publications
Schietroma M, Cecilia EM, Carlei F, Sista F, De Santis G, Lancione L, Amicucci G. Dexamethasone for the prevention of recurrent laryngeal nerve palsy and other complications after thyroid surgery: a randomized double-blind placebo-controlled trial. JAMA Otolaryngol Head Neck Surg. 2013 May;139(5):471-8. doi: 10.1001/jamaoto.2013.2821.
PubMed 23681030Yang C, Jung SM, Bae YK, Park SJ. The effect of ketorolac and dexamethasone on the incidence of sore throat in women after thyroidectomy: a prospective double-blinded randomized trial. Korean J Anesthesiol. 2017 Feb;70(1):64-71. doi: 10.4097/kjae.2017.70.1.64. Epub 2016 Nov 25.
PubMed 28184269Calkosinski I, Dobrzynski M, Calkosinska M, Seweryn E, Bronowicka-Szydelko A, Dzierzba K, Ceremuga I, Gamian A. [Characterization of an inflammatory response]. Postepy Hig Med Dosw (Online). 2009 Sep 3;63:395-408. Polish.
PubMed 19745226Waldron JL, Ashby HL, Cornes MP, Bechervaise J, Razavi C, Thomas OL, Chugh S, Deshpande S, Ford C, Gama R. Vitamin D: a negative acute phase reactant. J Clin Pathol. 2013 Jul;66(7):620-2. doi: 10.1136/jclinpath-2012-201301. Epub 2013 Mar 1.
PubMed 23454726Bennett NT, Schultz GS. Growth factors and wound healing: biochemical properties of growth factors and their receptors. Am J Surg. 1993 Jun;165(6):728-37. doi: 10.1016/s0002-9610(05)80797-4.
PubMed 8506974Gailit J, Clark RA. Wound repair in the context of extracellular matrix. Curr Opin Cell Biol. 1994 Oct;6(5):717-25. doi: 10.1016/0955-0674(94)90099-x.
PubMed 7530463Sakamoto K, Arakawa H, Mita S, Ishiko T, Ikei S, Egami H, Hisano S, Ogawa M. Elevation of circulating interleukin 6 after surgery: factors influencing the serum level. Cytokine. 1994 Mar;6(2):181-6. doi: 10.1016/1043-4666(94)90040-x.
PubMed 8032001Kalayci D, Dikmen B, Kacmaz M, Taspinar V, Ornek D, Turan O. [Plasma levels of interleukin-10 and nitric oxide in response to two different desflurane anesthesia flow rates]. Braz J Anesthesiol. 2014 Jul-Aug;64(4):292-8. doi: 10.1016/j.bjan.2013.06.009. Epub 2014 Jun 3. Portuguese.
PubMed 25096778Delogu G, Antonucci A, Signore M, Marandola M, Tellan G, Ippoliti F. Plasma levels of IL-10 and nitric oxide under two different anaesthesia regimens. Eur J Anaesthesiol. 2005 Jun;22(6):462-6. doi: 10.1017/s0265021505000797.
PubMed 15991511Turan A, Hesler BD, You J, Saager L, Grady M, Komatsu R, Kurz A, Sessler DI. The association of serum vitamin D concentration with serious complications after noncardiac surgery. Anesth Analg. 2014 Sep;119(3):603-612. doi: 10.1213/ANE.0000000000000096.
PubMed 25121616Pludowski P, Ducki C, Konstantynowicz J, Jaworski M. Vitamin D status in Poland. Pol Arch Med Wewn. 2016 Aug 9;126(7-8):530-9. doi: 10.20452/pamw.3479. Epub 2016 Aug 9.
PubMed 27509842
Study at a glance
From the registry record, last updated by the sponsor on 8 Feb 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Preoperative Oral Dexamethasone Supplementation on the Biochemical Parameters and Results of Surgical Treatment in Patients With Nontoxic Multinodular Goiter Undergoing Total Thyroidectomy.
- ClinicalTrials.gov ID
- NCT04412694
- Acronym / sponsor ID
- Dexa / MULODZ nr RNN/133/20/KE
- Conditions
- Hypocalcemia, Vitamin D Deficiency, Postoperative Complications, Postoperative Nausea, Postoperative Pain, Voice Hoarseness
- Keywords
- dexamethasone, hypocalcaemia, hypocalcemic symptoms, postoperative complications, vitamin D deficiency, cytokines, postoperative pain, postoperative nausea
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Medical University of LodzUniversity, hospital or other
- Study start
- 1 Jul 2020 (actual)
- Primary completion
- Sep 2022 (estimated)
- Study completion
- Dec 2022 (estimated)
- First posted
- 2 Jun 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Glucocorticoids are well known for their analgesic, anti-inflammatory, immunomodulatory and anti-emetic effects. Recovery time after thyroid surgery may depend on several factors, such as postoperative pain, nausea and vomiting, postoperative sore throat, voice disorders and symptomatic hypocalcaemia (low serum calcium level). However, there is little information in the literature about the preventive use of glucocorticosteroids in patients undergoing thyroid surgery. The aim of the study is to evaluate the clinical impact of preoperative oral dexamethasone supplementation on the surgical outcome in patients with multinodular goiter undergoing total thyroidectomy. Patients will be assigned to the supplementation group and the placebo group. In the supplementation group 8mg of dexamethasone will be administered orally one hour before surgery. In the postoperative period, the frequency and intensity of pain, nausea, vomiting, sore throat and hoarseness will be assessed. The incidence of symptoms of hypocalcaemia will also be evaluted. Preoperative and postoperative levels of vitamin D, cytokines, acute phase proteins and substances related to calcium metabolism will be measured in the blood. Cytokines levels in drainage fluid will also be assessed. The main hypothesis of the study is that in patients with supplementation postoperative discomfort and decrease in serum calcium and parathormone level and hypocalcemic symptoms will be less severe and the levels of proinflammatory substances will be decreased.
Detailed description
Recovery time after thyroid surgery may depend on several factors, such as postoperative pain, nausea and vomiting, postoperative sore throat, phonation disorders associated with recurrent laryngeal nerve palsy, and symptomatic postoperative hypocalcaemia associated with postoperative hypoparathyroidism.
Glucocorticoids are well known for their analgesic, anti-inflammatory, immunomodulatory and anti-emetic effects. However, there is little information in the literature on the prophylactic use of glucocorticosteroids in patients undergoing thyroid surgery. In some previous studies, preoperative intravenous dexamethasone supplementation was associated with a reduced incidence of postoperative laryngeal nerve palsy, postoperative hypoparathyroidism, and with less severe postoperative pain, postoperative sore throat, nausea and vomiting. Patients receiving supplementation also had decreased levels of inflammatory biochemical parameters and proinflammatory cytokines.
Vitamin D deficiency is widespread in Poland. Vitamin D status has an impact on the postoperative complications in surgical patients. In previous study serum 25-hydroxyvitamin D is also suggested as a negative acute phase reactant, which has implications for acute and chronic inflammatory diseases. According to the authors, serum 25-hydroxyvitamin D level is an unreliable biomarker of vitamin D status after acute inflammatory insult.
In the early stages of inflammation, phagocytic cells and endothelium secrete proinflammatory cytokines, which include: interleukins: IL-1 α / β, IL-6, IL-8, TNF. The antagonistic group is anti-inflammatory cytokines, which include interleukins: IL-4, -5, -10, -13, produced by Th2 lymphocytes. These cytokines reduce the amount of interleukins secreted by Th1 lymphocytes.
Changes in the levels of proinflammatory and anti-inflammatory cytokines in the postoperative period were found in studies related to the assessment of surgical trauma. Pro-inflammatory interleukin 1 and interleukin 6 play an important role in many biological processes such as inflammation, sepsis and wound healing. Interleukin 6 expression is proportional to the extent of the surgical trauma. In turn, interleukin 10 is known as a cytokine that inhibits cytokine synthesis. Is one of the strongest immunosuppressive agents.
The aim of my study is to evaluate the impact of preoperative oral dexamethasone supplementation on the biochemical parameters and results of surgical treatment in patients with nontoxic multinodular goiter undergoing total thyroidectomy.
Patients admitted to the Department of General and Oncological Surgery, Medical University of Lodz with preoperative diagnosis of nontoxic multinodular goitre undergoing total thyroidectomy will be inculded to the study.
After obtaining written informed consent from all participants during a preoperative visit, they will be randomized to the supplementation group and the placebo group. The study will be a prospective, placebo-controlled and double-blind (for patient and surgeon) research.
Intervention: In the supplementation group a single dose of 8mg of dexamethasone will be given orally one hour before surgery (Dexamethasone Krka tablets (8mg), Warsaw, Poland). In the placebo group patients will receive a single tablet of sweetener one hour before operation (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria).
Preoperatively in the group of all enrolled patients (in the supplementation group and in the placebo group) following tests will be measured in serum: blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10, thyroid stimulating hormone, free thyroxine, free triiodothyronine.
Total thyroidectomies with routine identification of the recurrent laryngeal nerves and parathyroid glands via a transverse cervicotomy under general anaesthesia will be performed by 3 experienced surgeons.
During the total thyroidectomy the number of parathyroid glands found intraoperatively will be registered.
At 6 hour after surgery in the group of all enrolled patients following tests will be measured in serum: blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium. In addiction, at 6 hour after surgery the incidence and intensity of symptomatic hypocalcaemia, postoperative pain (according to VAS scale), postoperative nausea and vomiting, postoperative sore throat and hoarseness will be evaluated.
At 24 hour after surgery in the group of all enrolled patients following tests will be measured in serum: blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10. Additionally, the level of interleukin 1β, interleukin 6 and interleukin 10 will be evaluated in drainage fluid. In addiction, at 24 hour after surgery the incidence and intensity of symptomatic hypocalcaemia, postoperative pain (according to Visual Analogue Scale - VAS scale), postoperative nausea and vomiting, postoperative sore throat and hoarseness will be evaluated.
The laboratory parameters will be determined by electrochemiluminescence on the Cobas E411 analyzer and spectrophotometric method on the AU680, Beckman Coulter analyzer. 25-hydroxyvitamin D levels will be measured using the chemiluminescent microparticle immunoassay (CMIA) (Architect 25-OHD). Interleukins levels will be determined by enzyme immunoassay method (EIA) (DGR Medtek) on ElizaMat 2 X analyzer.
Hypocalcemic symptoms will be categorized as mild (a tingling sensation and numbness of the hands or feet and perioral numbness) or severe (a positive Chvostek sign, Trousseau sign, tetany, and carpopedal spasms).
Postoperative hypocalcaemia will be defined as corrected calcium levels <2.0 mmol/l, even if recorded in one measurement only.
In both groups participants who will develop postoperative hypoparathyroidism (parathormone level <1.6 pmol/l at 6 or 24 hour after surgery) or symptomatic hypocalcaemia during hospitalisation will be treated with oral calcium (3 g/d - taken 1 g every 8 hours) and vitamin D derivatives (1 ug/d alfacalcidol taken once).
Intravenous calcium gluconate will be administered if symptoms persist despite oral supplementation.
Patients with symptomatic hypocalcaemia will receive supplementation until the symptoms subside. The treatment will be extended to 6 weeks in patients with hypoparathyroidism on the day of discharge.
The data will be statistically analysed. The main hypothesis of the study is that in patients with supplementation postoperative discomfort and decrease in serum calcium and parathormone level and hypocalcemic symptoms will be less severe and the levels of proinflammatory substances will be decreased. Vitamin D deficiency is probably common in operated patients and postoperative 25-hydroxyvitamin D levels are lower than those measured preoperatively.
The use of oral dexamethasone might be an effective strategy of prevention of complications after total thyroidectomy.
To the best of our knowledge, this is a pioneering study assessing the usefulness of preventive oral dexamethasone supplementation before total thyroidectomy in homogeneous group of patients with nontoxic multinodular goiter undergoing total thyroidectomy.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
- Model description
- Patients will be randomly assigned (coin toss) to the supplementation group (preoperative oral supplementation of dexamethasone (8mg in one dose) taken one hour before surgery) and to the placebo group (preoperative oral supplementation of sweetener taken one hour before surgery).
| Arm | Type | Receives |
|---|---|---|
| supplementation group | Experimental | Drug: Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland)., Diagnostic Test: Preoparative blood laboratory tests, Diagnostic Test: Postoperative laboratory blood tests at 6 hour, Diagnostic Test: Postoperative laboratory blood tests at 24 hour, Diagnostic Test: Postoperative laboratory drainage fluid tests at 24 hour, Procedure: Total thyroidectomy, Other: Symptomatic hypocalcaemia at 6 hour, Other: Symptomatic hypocalcaemia at 24 hour, Other: Postoperative pain at 6 hour, Other: Postoperative pain at 24 hour, Other: Postoperative nausea and vomiting at 6 hour, Other: Postoperative nausea and vomiting at 24 hour, Other: Postoperative sore throat and hoarseness at 6 hourPatients will receive preoperative oral supplementation of 8mg of dexamethasone (Dexamethasone Krka tablets (8mg), Warsaw, Poland) in a single dose taken once one hour before surgery. At 6 and 24 hour after surgery, clinical and laboratory parameters will be measured and evaluated. |
| placebo group | Placebo comparator | Drug: Placebo oral sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria)., Diagnostic Test: Preoparative blood laboratory tests, Diagnostic Test: Postoperative laboratory blood tests at 6 hour, Diagnostic Test: Postoperative laboratory blood tests at 24 hour, Diagnostic Test: Postoperative laboratory drainage fluid tests at 24 hour, Procedure: Total thyroidectomy, Other: Symptomatic hypocalcaemia at 6 hour, Other: Symptomatic hypocalcaemia at 24 hour, Other: Postoperative pain at 6 hour, Other: Postoperative pain at 24 hour, Other: Postoperative nausea and vomiting at 6 hour, Other: Postoperative nausea and vomiting at 24 hour, Other: Postoperative sore throat and hoarseness at 6 hour, Other: Postoperative sore throat and hoarseness at 24 hourPatients will receive preoperative oral supplementation of sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria) taken once in a single dose one hour before surgery. At 6 and 24 hour after surgery, clinical and laboratory parameters will be measured and evaluated. |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- patient's consent
- adult patients
- preoperative diagnosis of nontoxic multinodular goiter
- total thyroidectomy
Key exclusion criteria (39 listed)
- lack of patient's consent
- hyperthyroidism currently or in the past
- retrosternal goiter
- thyroid malignanacy or suspected malignant thyroid tumor
- parathyroids disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland).Also: SupplementationPreoperative oral dexamathasone supplementation in a single dose of 8mg. | Drug | supplementation group |
| Placebo oral sweetener (Clio tablets, sweetener with a dispenser, Instantina GES, Vienna, Austria).Also: PlaceboPreoperative oral supplementation of sweetener in a single dose. | Drug | placebo group |
| Preoparative blood laboratory testsAlso: preoperative blood testPreoperative parameters such as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10, thyroid stimulating hormone, free thyroxine, free triiodothyronin will be measured in serum. | Diagnostic test | placebo group, supplementation group |
| Postoperative laboratory blood tests at 6 hourAlso: blood tests 6 hourAt 6 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium will be measured in serum. | Diagnostic test | placebo group, supplementation group |
| Postoperative laboratory blood tests at 24 hourAlso: blood tests 24 hourAt 24 hour after surgery such parameters as blood count, calcium, inorganic phosphates, albumin, alkaline phosphatase, C reactive protein, procalcitonin, 25-hydroxyvitamin D, fibrinogen, parathormone, magnesium, interleukin 1β, interleukin 6, interleukin 10 will be measured in serum. | Diagnostic test | placebo group, supplementation group |
| Postoperative laboratory drainage fluid tests at 24 hourAlso: drainage fluid tests 24 hourAt 24 hour after surgery such parameters as interleukin 1β, interleukin 6, interleukin 10 will be measured in drainage fluid. | Diagnostic test | placebo group, supplementation group |
| Total thyroidectomyAlso: thyroidectomyPatients will undergo total thyroidectomy under general anesthesia. | Procedure or surgery | placebo group, supplementation group |
| Symptomatic hypocalcaemia at 6 hourAlso: symptoms 6 hourAt 6 hour after surgery patients will be assessed for signs of hypocalcaemia. | Other | placebo group, supplementation group |
| Symptomatic hypocalcaemia at 24 hourAlso: symptoms 24 hourAt 24 hour after surgery patients will be assessed for signs of hypocalcaemia. | Other | placebo group, supplementation group |
| Postoperative pain at 6 hourAlso: pain 6 hourAt 6 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS). | Other | placebo group, supplementation group |
| Postoperative pain at 24 hourAlso: pain 24 hourAt 24 hour after surgery the incidence and intensity of postoperative pain will be evaluated according to Visual Analogue Scale (VAS). | Other | placebo group, supplementation group |
| Postoperative nausea and vomiting at 6 hourAlso: nausea 6 hourAt 6 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated. | Other | placebo group, supplementation group |
| Postoperative nausea and vomiting at 24 hourAlso: nausea 24 hourAt 24 hour after surgery the incidence and intensity of postoperative nausea and vomiting will be evaluated. | Other | placebo group, supplementation group |
| Postoperative sore throat and hoarseness at 6 hourAlso: hoarseness 6 hourAt 6 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated. | Other | placebo group, supplementation group |
| Postoperative sore throat and hoarseness at 24 hourAlso: hoarseness 24 hourAt 24 hour after surgery the incidence and intensity of postoperative sore throat and hoarseness will be evaluated. | Other | placebo group |
Primary outcome
Postoperative hypocalcaemia
Time frame: preoperatively and at 6 and 24 hour after surgery
To evaluate the incidence of laboratory hypocalcaemia (corrected calcium serum level <2.0 mmol/l), the change in calcium levels and symptomatic hypocalcaemia in the postoperative period in the supplementation group and in the placebo group.
Postoperative hypoparathyroidism
Time frame: preoperatively and at 6 and 24 hour after surgery
To evaluate the incidence of hypoparathyroidism (parathormone serum level <1.6 pmol/l) and the change in parathormone levels in the postoperative period in the supplementation group and in the placebo group.
5 secondary outcomes
Postoperative pain
Time frame: at 6 and 24 hour after surgery
Postoperative nausea on a verbal rating scale
Time frame: at 6 and 24 hour after surgery
Postoperative vomiting on a verbal rating scale
Time frame: at 6 and 24 hour after surgery
Postoperative sore throat on a verbal rating scale
Time frame: at 6 and 24 hour after surgery
Postoperative hoarseness on a verbal rating scale
Time frame: at 6 and 24 hour after surgery
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Feb 2022.
- Background: PubMed 23681030Schietroma M, Cecilia EM, Carlei F, Sista F, De Santis G, Lancione L, Amicucci G. Dexamethasone for the prevention of recurrent laryngeal nerve palsy and other complications after thyroid surgery: a randomized double-blind placebo-controlled trial. JAMA Otolaryngol Head Neck Surg. 2013 May;139(5):471-8. doi: 10.1001/jamaoto.2013.2821.
- Background: PubMed 28184269Yang C, Jung SM, Bae YK, Park SJ. The effect of ketorolac and dexamethasone on the incidence of sore throat in women after thyroidectomy: a prospective double-blinded randomized trial. Korean J Anesthesiol. 2017 Feb;70(1):64-71. doi: 10.4097/kjae.2017.70.1.64. Epub 2016 Nov 25.
- Background: PubMed 19745226Calkosinski I, Dobrzynski M, Calkosinska M, Seweryn E, Bronowicka-Szydelko A, Dzierzba K, Ceremuga I, Gamian A. [Characterization of an inflammatory response]. Postepy Hig Med Dosw (Online). 2009 Sep 3;63:395-408. Polish.
- Background: PubMed 23454726Waldron JL, Ashby HL, Cornes MP, Bechervaise J, Razavi C, Thomas OL, Chugh S, Deshpande S, Ford C, Gama R. Vitamin D: a negative acute phase reactant. J Clin Pathol. 2013 Jul;66(7):620-2. doi: 10.1136/jclinpath-2012-201301. Epub 2013 Mar 1.
- Background: PubMed 8506974Bennett NT, Schultz GS. Growth factors and wound healing: biochemical properties of growth factors and their receptors. Am J Surg. 1993 Jun;165(6):728-37. doi: 10.1016/s0002-9610(05)80797-4.
- Background: PubMed 7530463Gailit J, Clark RA. Wound repair in the context of extracellular matrix. Curr Opin Cell Biol. 1994 Oct;6(5):717-25. doi: 10.1016/0955-0674(94)90099-x.
- Background: PubMed 8032001Sakamoto K, Arakawa H, Mita S, Ishiko T, Ikei S, Egami H, Hisano S, Ogawa M. Elevation of circulating interleukin 6 after surgery: factors influencing the serum level. Cytokine. 1994 Mar;6(2):181-6. doi: 10.1016/1043-4666(94)90040-x.
- Background: PubMed 25096778Kalayci D, Dikmen B, Kacmaz M, Taspinar V, Ornek D, Turan O. [Plasma levels of interleukin-10 and nitric oxide in response to two different desflurane anesthesia flow rates]. Braz J Anesthesiol. 2014 Jul-Aug;64(4):292-8. doi: 10.1016/j.bjan.2013.06.009. Epub 2014 Jun 3. Portuguese.
- Background: PubMed 15991511Delogu G, Antonucci A, Signore M, Marandola M, Tellan G, Ippoliti F. Plasma levels of IL-10 and nitric oxide under two different anaesthesia regimens. Eur J Anaesthesiol. 2005 Jun;22(6):462-6. doi: 10.1017/s0265021505000797.
- Background: PubMed 25121616Turan A, Hesler BD, You J, Saager L, Grady M, Komatsu R, Kurz A, Sessler DI. The association of serum vitamin D concentration with serious complications after noncardiac surgery. Anesth Analg. 2014 Sep;119(3):603-612. doi: 10.1213/ANE.0000000000000096.
- Background: PubMed 27509842Pludowski P, Ducki C, Konstantynowicz J, Jaworski M. Vitamin D status in Poland. Pol Arch Med Wewn. 2016 Aug 9;126(7-8):530-9. doi: 10.20452/pamw.3479. Epub 2016 Aug 9.
- Individual participant dataSharing planned: Yes. All IPD will be included in planned publication.
Related trials for Hypocalcemia
Recruiting
NIRAF-Guided Parathyroid Identification During Thyroidectomy
Hypocalcemia, Hypoparathyroidism
RecruitingObservational study
Postoperative Hypocalcemia After Thyroidectomy
Thyroid Nodule, Thyroid Dysfunction
Not yet recruitingObservational study
Ionized Calcium as a Severity Marker in Septic Shock Patients
Sepsis, Septic Shock
Active, not recruitingPhase 2
Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in Adults
Hypoparathyroidism
Active, not recruitingPhase 3
Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1
Autosomal Dominant Hypocalcemia (ADH)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Anna Grzegory, MD principal investigator
Medical University of Lodz, Poland
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Dexamethasone oral tablet 8mg (Dexamethasone Krka tablets(8mg), Warsaw, Poland)., Preoparative blood laboratory tests and Postoperative laboratory blood tests at 6 hour in people with Hypocalcemia and Vitamin D Deficiency, run by Medical University of Lodz at 1 site in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 39 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 Feb 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Anna Grzegory, MD (695720008 ext. +48, an.grzegory@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative hypocalcaemia (time frame: preoperatively and at 6 and 24 hour after surgery). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04412694, which also lists 11 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Feb 2022.